Application of jejunal interposition after radical proximal gastrectomy

To explore an ideal method of digestive tract reconstruction and tolerance to adjuvant chemotherapy after radical proximal gastrectomy. Thirty patients in the reconstruction group were treated by jejunal interposition, and other 30 patients received gastroesophagostomy (control group). The operation...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá zhŏngliú zázhì Vol. 35; no. 7; p. 530
Main Authors Zhang, Bin, Ji, She-qing, Hua, Ya-wei, Liu, Ying-qiang
Format Journal Article
LanguageChinese
Published China 01.07.2013
Subjects
Aged
Anastomosis, Surgical - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
C-Reactive Protein - metabolism
Chemotherapy, Adjuvant
Female
Fluorouracil - therapeutic use
Follow-Up Studies
Gastrectomy - adverse effects
Gastrectomy - methods
Gastroesophageal Reflux - etiology
Humans
Jejunum - surgery
Leucovorin - therapeutic use
Male
Middle Aged
Operative Time
Organoplatinum Compounds - therapeutic use
Quality of Life
Reconstructive Surgical Procedures - adverse effects
Reconstructive Surgical Procedures - methods
Retrospective Studies
Stomach Neoplasms - drug therapy
Stomach Neoplasms - metabolism
Stomach Neoplasms - surgery
Systemic Inflammatory Response Syndrome - etiology
Online AccessGet more information

Cover

More Information
Summary:To explore an ideal method of digestive tract reconstruction and tolerance to adjuvant chemotherapy after radical proximal gastrectomy. Thirty patients in the reconstruction group were treated by jejunal interposition, and other 30 patients received gastroesophagostomy (control group). The operation time, operation risk, occurrence of reflux esophagitis and postoperative 1-, 3-, 6-month nutrition statuses were evaluated. Forty-three patients received postoperative adjuvant chemotherapy with mFOLFOX-6 and tolerance to the chemotherapy was assessed. The operation time of the reconstructional group was (162.2 ± 14.0)min and that of the control group was (137.6 ± 18.9)mi, with a statistically significant difference. (t = -5.7, P<0.01). There were no significant differences of operation risk, postoperative 2-, 4-, and 6-day C-reactive protein, 2-, 4- and 6-day systemic inflammatory response syndrome between the two groups. The differences of the occurrence of postoperative 1-, 3- and 6-month reflux esophagitis and
ISSN:0253-3766